Cytokines News and Research

Latest Cytokines News and Research

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that consolidation treatment with fractionated yttrium-90 (Y-90) labeled epratuzumab, after induction therapy with rituximab and CHOP (R-CHOP) chemotherapy, improved remission status of adult patients with diffuse large B-cell lymphoma (DLBCL), a form of aggressive lymphoma.

7 Dec 2010

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that combination therapy with epratuzumab and rituximab was effective, with durable complete responses in one-third of evaluable patients, and was very well tolerated by patients with previously untreated follicular lymphoma (FL).

7 Dec 2010

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.

6 Dec 2010

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today the presentation of new preclinical data for CYC065, a novel, orally-available, cell cycle kinase inhibitor. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Ligand Pharmaceuticals Incorporated today announced that multiple clinical studies of dinaciclib (SCH 727965) will be presented by Merck at the upcoming 52nd American Society of Hematology Annual Meeting being held in Orlando, Florida at the Orange County Convention Center, December 4-7, 2010.

4 Dec 2010

Study on animal model may impact treatment of stroke

The results of two studies published in the current issue of Cell Transplantation (19:9) using animal models of cerebral ischemia and ischemic stroke in rats may significantly impact the treatment of stroke in humans.

2 Dec 2010

Bone marrow stromal stem cells may aid in stroke recovery: Research

A research study from the Farber Institute for Neurosciences and the Department of Neuroscience at Thomas Jefferson University determines bone marrow stromal stem cells may aid in stroke recovery. The results can be found in Cell Transplantation, The Regenerative Medicine Journal, issue 19(9).

2 Dec 2010

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases.

2 Dec 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Depressed and suicidal individuals linked to low levels of stress hormone cortisol

Depressed and suicidal individuals have low levels of the stress hormone cortisol in their blood and saliva. They also have substances in their spinal fluid that suggest there is increased inflammation in the brain. These findings could help to develop new methods for diagnosing and treating suicidal patients.

29 Nov 2010

Scientists reveal long-standing mystery about HIV infection

Scientists at Gladstone Institute of Virology and Immunology have solved a long-standing mystery about HIV infection-namely how HIV promotes the death of CD4 T cells.

25 Nov 2010

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

Idera Pharmaceuticals, Inc. announced today that it is presenting preclinical data from a study evaluating the mechanism of action of one of its Toll-like receptor (TLR) 7 and TLR9 antagonist candidates in a model of hyperlipidemia.

18 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Cyplasin Biomedical is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has selected Aurobindo Pharma located in Hyderabad , India to supply the active pharmaceutical ingredient (API) component for its Ribavirin drug product called C-Virin.

15 Nov 2010

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

NanoViricides, Inc. reports that its optimized FluCide™ drug candidates achieved dramatic reduction in viral load within the lungs of animals infected with a lethal dose of H1N1 influenza virus.

15 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Cytokines News and Research

Latest Cytokines News and Research

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Study on animal model may impact treatment of stroke

Bone marrow stromal stem cells may aid in stroke recovery: Research

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

Scientists identify signaling pathway and receptor for thymosin beta 4

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Depressed and suicidal individuals linked to low levels of stress hormone cortisol

Scientists reveal long-standing mystery about HIV infection

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cytokines News and Research

Latest Cytokines News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in